(Q33875597)

24755199

29 July 2017

title

Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer (English)

1 reference

29 July 2017

1 reference

0 references

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Guillermo Armaiz-Pena

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

15

Joseph M DeSimone

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

16

Anil K Sood

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

12

J Christopher Luft

1 reference

31 May 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

10

Tojan B Rahhal

1 reference

31 May 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

Kshipra M Gharpure

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Kevin S Chu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Charles J Bowerman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Takahito Miyake

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Sunila Pradeep

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Selanere L Mangala

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Hee-Dong Han

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Sherry Y Wu

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Mary E Napier

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Gabriel Lopez-Berestein

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

1 reference

22 April 2014

1 reference

24755199

Molecular Cancer Therapeutics

29 July 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

1750-1757

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53.

31 May 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Metronomic chemotherapy for cancer treatment: a decade of clinical studies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Potent engineered PLGA nanoparticles by virtue of exceptionally high chemotherapeutic loadings

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Regulation of tumor angiogenesis by EZH2.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

The anti-angiogenic basis of metronomic chemotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Ovarian cancer: strategies for overcoming resistance to chemotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Metronomic scheduling: the future of chemotherapy?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

What Is the Evidence That Tumors Are Angiogenesis Dependent?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4090269

Long-term remission in a patient with heavily pretreated, advanced ovarian cancer achieved by bevacizumab and metronomic cyclophosphamide treatment

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24755199

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1535-7163.MCT-13-0930

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24755199%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

24755199

1 reference